As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…
HOME > ORGANIZATION
ORGANIZATION
- OTC Industry Group Keen on Expanding Self-Medication Tax Break: Chief
January 18, 2017
- JPMA Eager for Its Active Involvement in Drug Pricing Debates: Chief
January 18, 2017
- JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
January 18, 2017
- JGA Corrects Generic Share Data for Past 3 Years; July-Sept. Share at 65.1%
January 16, 2017
- With Annual Revisions, Drug Wholesalers Will Be Negotiating Delivery Prices All Year: JPWA Chief
January 12, 2017
- Tokyo Pharma Chief Naito Prods Govt to Secure Predictability of Pricing System
January 10, 2017
- Building Personal Relationships Will Be Crucial: FPMAJ Director General
January 6, 2017
- Annual Price Revisions Must Not Adversely Affect Distribution Environment: JPWA
December 26, 2016
- Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
December 26, 2016
- FPMAJ Accepts PMDA’s Fee Raise Plan, but Wants Tradeoff
December 16, 2016
- JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
- Daratumumab Affects Transfusion Tests, Scientific Societies Warn
December 13, 2016
- Ongoing Discussions without Chuikyo Deplorable: JPWA Head
December 12, 2016
- Annual Price Revisions Will Demotivate Pharmas, Foreign HQs Harboring Serious Concerns: PhRMA Japan Chief
December 9, 2016
- Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
- JPWA Shows Firm Opposition to Annual Revisions
December 5, 2016
- Annual Price Revisions of All Drugs Unacceptable: JMA Chief
December 1, 2016
- Japan, US, Europe Trade Groups Vehemently Oppose Annual Price Revisions
December 1, 2016
- JGA Rebuts Govt Panel Members’ Pricing Reform Proposals in Emergency Statement
November 30, 2016
- Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
November 28, 2016
ページ
Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…
To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…
While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…